The American healthcare company CVS Health Corporation is the owner of a number of well-

known brands, including Aetna, CVS Caremark, and CVS Pharmacy, which operates as a network

of retail pharmacies. Other well-known brands owned by CVS Health Corporation include CVS

Specialty and CVS Health Insurance. The increase in net revenues from 2022 to 2021 was $3.6

billion, while the increase in net revenues from 2021 to 2020 was $16.0 billion. Revenues in 2019

and 2018 also increased. The upward trend suggests that CVS's performance in other areas, such as

the revenue from pharmacy services and the revenue from retail pharmacy services, has an effect on

the company's total net sales. Despite this, the year 2019 saw a decrease of -2.35% in comparison to

the previous year's gain in gross profit. The dividends paid out by CVS Caremark have shown a

compound annual growth rate of 29.25% over the last five years. At the end of November 2022, the

common stock of CVS Caremark was selling at a multiple of 34 times the company's profits per

share. The CVS Caremark Corporation is expected to create daily returns of 0.3038%, assuming a

return distribution volatility of 1.0634% over a time horizon of an investment of sixty days. As a

result, Mr. Donothing considers CVS to be an excellent investment for the long run.
CVS Caremark pharmacy background information CVS Caremark pharmacy is one of the most

well-known pharmacies in the United States that has effectively dominated the industry on a wider

scale. The group today operates over 7600 retail pharmacies and ensures a steady supply of medical

facilities. This, along with the fact that the company is led by a strong management team led by

CEO Larry J. Merlo, has provided the firm a substantial competitive edge in fulfilling its many

goals. Because of the flawless integration of varied company-wide processes, the business has an

outstanding reputation for delivering medical services. In his remarks in the 2013 annual report, the

CEO said that the firm has adopted a number of measures as a pharmacy innovation company to

decrease the risks associated with the pharmacy technology industry's dynamic environment. This

has been made considerably simpler by the introduction of a sophisticated information system

designed to facilitate activity coordination inside the company. To do this, the company has grown

its 33 million customer service centers and 3.2 million annual pharmacy advisor interventions.

These have been done to increase the amount of patients that visit this pharmacy. The method seems

to have been effective, since there are currently 1.8 billion visits every year. The number of minute
clinic visits has also increased to 4 million every year. This displays a strong sense of growth for the

company in terms of profitability and target market. This essay is meant to give a comprehensive

financial analysis of this illustrious firm, paying particular attention to different analytical

methodologies that would reveal the genuine financial and performance status of the corporation. In

this instance, the horizontal (trend) analysis will get a lot of attention. To do this, several financial

statement items from 2011 to 2013 would need to be compared. Second, in this case, a vertical

inspection is critical. This would need a detailed examination of financial ratios, which, given the

circumstances, would disclose how the organization fared throughout the aforementioned time

period. Third, it is critical to scrutinize the research in terms of the gain on the shareholder's wealth.

In this case, a closer look at the earnings per share, dividend per share, and accompanying constant

analysis is critical.